Widespread extrahippocampal NAA/(Cr+Cho) abnormalities in TLE with and without mesial temporal sclerosis
Susanne G. Mueller(University of California, San Francisco), Kenneth D. Laxer(California Pacific Medical Center), Jerome Barakos(Sutter Health), Michael W. Weiner(University of California, San Francisco), Ian Cheong(Western University), Paul A. Garcia(University of California, San Francisco), Daniel Finlay(Institute for Neurodegenerative Disorders), Cathy Scanlon(Ollscoil na Gaillimhe – University of Galway), Andreas Ebel(University of California, San Francisco)
Cited by 30
Related Papers
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—An emerging role for gut microbiome
|Alzheimer s & Dementia|2018|690